Drugs Containing Excipient (Inactive Ingredient) RASPBERRY

Branded drugs containing RASPBERRY excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn Operating Company LLC	AMICAR	aminocaproic acid	49411-052	RASPBERRY

Generic drugs containing RASPBERRY excipient

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	prednisolone sodium phosphate	0121-0902	RASPBERRY
Pharmaceutical Associates Inc	oxycodone hydrochloride	0121-4839	RASPBERRY
Sandoz Inc	amoxicillin and clavulanate potassium	0781-6139	RASPBERRY
Marlex Pharmaceuticals Inc	dexamethasone	10135-795	RASPBERRY
7-Eleven	ibuprofen	10202-711	RASPBERRY
Rising Pharma Holdings Inc	pyridostigmine bromide	16571-833	RASPBERRY
ATLANTIC BIOLOGICALS CORP	hydromorphone hydrochloride	17856-0386	RASPBERRY

Raspberry Pharmaceutical Excipient Market Dynamics, Regulatory Status, Patent Risk, and Financial Trajectory

Last updated: August 1, 2026

Raspberry is a niche pharmaceutical excipient category used mainly as a flavoring agent, taste-masking component, color contributor, and patient-acceptance aid in oral dosage forms. It is not a single chemically defined excipient. Commercial products may contain natural raspberry flavor, synthetic flavor compounds, raspberry juice concentrate, fruit powder, raspberry-derived anthocyanins, or blends with sweeteners and acids.

The category has limited standalone financial disclosure because suppliers generally report raspberry products within broader flavor, excipient, food ingredient, or specialty formulation businesses. Its commercial outlook is tied to pediatric medicines, orally disintegrating tablets, chewables, syrups, suspensions, gummies, and over-the-counter products rather than to high-value active pharmaceutical ingredients.

What is raspberry used for in pharmaceutical formulations?

Raspberry is primarily used to improve palatability and patient acceptance.

Application	Typical dosage form	Commercial purpose
Flavoring	Oral solutions, syrups, suspensions	Masks bitterness, acidity, or medicinal odor
Taste-masking blend	Chewable tablets, orally disintegrating tablets	Improves pediatric and geriatric compliance
Color contribution	Liquids, gummies, lozenges	Supports product identification and consumer appeal
Fruit-derived solids	Powders, sachets, chewables	Adds flavor, solids, and label-positioning value
Anthocyanin source	Select oral products and supplements	Provides red-purple coloration, subject to stability constraints
Combination flavor system	Multivitamin, electrolyte, and OTC formulations	Stabilizes flavor across sweetener, acid, and active-ingredient systems

Raspberry flavor is often combined with sucrose, sucralose, sorbitol, xylitol, citric acid, malic acid, masking agents, and cooling or warming agents. A formulation may be marketed as raspberry while relying on a chemically reconstructed flavor system rather than raspberry fruit material.

Is raspberry a single pharmaceutical excipient?

No. “Raspberry” is a product descriptor rather than a single pharmacopeial chemical entity.

Commercial materials generally fall into four categories:

1. Natural raspberry flavor derived from fruit, juice, extracts, or natural flavor constituents.
2. Nature-identical or synthetic flavor systems containing compounds associated with raspberry aroma.
3. Raspberry fruit powders or concentrates containing sugars, acids, pigments, volatile compounds, and other plant constituents.
4. Raspberry color systems based on anthocyanins or blended food colorants.

This distinction affects regulatory documentation, specifications, stability, allergen review, microbiological controls, residual solvents, pesticide limits, and supply-chain risk.

Natural raspberry materials can have higher batch variability than synthetic flavor systems. Synthetic or reconstructed flavors generally offer better lot-to-lot consistency and lower cost, but they may not support the same clean-label or natural-positioning claims.

What is the FDA regulatory status of raspberry excipients?

Raspberry flavoring substances are generally regulated through the U.S. food additive and flavor framework rather than through an approval pathway specific to pharmaceuticals.

Relevant regulatory routes include:

• Food additive regulations under Title 21 of the Code of Federal Regulations.
• Substances generally recognized as safe, or GRAS, when used under permitted conditions.
• FEMA GRAS determinations for individual flavoring substances.
• The FDA Inactive Ingredient Database for precedent involving specific inactive ingredients and dosage forms.
• New Drug Application review of the complete formulation, including excipient identity, quality, quantity, and safety.

A flavor may be acceptable in food use but still require pharmaceutical-quality qualification. Drug manufacturers must establish identity, purity, microbiological quality, stability, manufacturing controls, and suitability for the intended route and dose.

The FDA does not generally approve “raspberry” as a universal pharmaceutical excipient independent of a defined composition. A finished drug application must identify the actual material and its concentration.

What documentation do drug manufacturers require?

Typical qualification packages include:

• Certificate of analysis
• Full qualitative and quantitative composition
• Manufacturing process description
• Residual solvent data
• Heavy-metal and elemental-impurity data
• Microbial limits
• Pesticide and mycotoxin controls for agricultural materials
• Allergen and genetically modified organism statements
• Stability data
• Country-of-origin information
• Change-control commitments
• Safety and toxicology information
• Extractables and leachables data where relevant

Natural raspberry-derived materials may require more extensive agricultural and microbiological documentation than synthetic flavor blends.

Is raspberry listed in the FDA Orange Book?

Raspberry is not an active pharmaceutical ingredient and does not have an Orange Book patent listing as an excipient.

The Orange Book identifies approved drug products and certain patents or regulatory exclusivities associated with those products. It does not create a standalone patent or exclusivity right for common flavoring ingredients such as raspberry.

A drug containing raspberry flavor may have Orange Book-listed patents covering:

• The active ingredient
• A controlled-release system
• A liquid or suspension formulation
• A taste-masking technology
• A specific combination of active ingredients
• A manufacturing process
• A method of treatment

Those rights would protect the finished drug or formulation, not the general use of raspberry flavor.

What patents protect raspberry pharmaceutical formulations?

There is no broad patent monopoly over raspberry as a flavor or pharmaceutical excipient. Patent protection can arise from the specific formulation architecture.

Potentially protectable subject matter includes:

Patent subject	Typical claim focus
Taste masking	Coated particles, ion-exchange resins, lipid barriers, complexation
Oral liquid	pH range, preservative system, viscosity modifier, flavor blend
Chewable tablet	Compression profile, flavor ratio, sweetener system, disintegration
Orally disintegrating tablet	Rapid dispersion, bitterness suppression, particle engineering
Gummies	Gel matrix, water activity, active loading, flavor stability
Stability system	Protection against oxidation, light, hydrolysis, or anthocyanin degradation
Manufacturing process	Mixing order, granulation, coating, drying, or encapsulation
Combination product	Specific active-excipient interaction or dosage regimen

A claim directed only to “a pharmaceutical composition comprising raspberry flavor” would face significant novelty and obviousness challenges unless paired with a technically meaningful limitation. Stronger claims usually require a defined composition, concentration range, performance result, or manufacturing step.

How strong is the patent estate for raspberry excipient products?

The standalone patent estate is weak. The relevant intellectual-property value usually sits in the formulation platform, not in raspberry itself.

Patent strength is higher when the formulation demonstrates:

• A measurable reduction in bitterness or aftertaste
• Improved chemical or microbial stability
• A defined dissolution or disintegration profile
• Better patient adherence in a clinically relevant population
• A narrow excipient ratio that produces an unexpected result
• Compatibility with a difficult active ingredient
• Commercially valuable protection for a pediatric or specialty product

The same raspberry flavor can be used by multiple manufacturers if they procure it from different suppliers or recreate the flavor profile without copying protected formulation claims.

When does raspberry lose exclusivity?

Raspberry does not have a fixed pharmaceutical exclusivity date.

There is no standard patent expiration date, Hatch-Waxman exclusivity period, or regulatory exclusivity period attached to the ingredient category. Exclusivity depends on the protected product in which raspberry is used.

For a finished drug, relevant periods can include:

• New chemical entity exclusivity: generally five years in the United States.
• Three-year approval-based exclusivity for certain new clinical investigations.
• Orphan-drug exclusivity: generally seven years.
• Pediatric exclusivity: six additional months when granted.
• Patent terms: generally 20 years from the earliest effective nonprovisional filing date, subject to adjustments and disclaimers.
• Patent-term extension: potentially available for qualifying regulatory delays.

These periods belong to the active drug or approved product. They do not prevent competitors from using raspberry flavor in unrelated products.

How do Paragraph IV challenges affect raspberry formulations?

A Paragraph IV certification can challenge a listed patent for a finished drug containing raspberry flavor, but it would not normally challenge raspberry as an excipient.

A generic applicant may assert that:

• The listed formulation patent is invalid.
• The patent is not infringed.
• The generic product uses a different flavor system.
• The patent claims do not cover the proposed concentration or dosage form.
• The patent is unenforceable.

The commercial impact depends on whether the formulation patent is essential to the reference product. If the reference drug has multiple formulation patents and the generic can design around the raspberry-related claims, the flavor component is unlikely to delay entry.

For conventional oral liquids and chewables, formulation patents can be vulnerable if they claim broad combinations of ordinary sweeteners, acids, preservatives, and flavors without a demonstrated technical effect.

What manufacturing and supply-chain barriers affect raspberry excipients?

The principal barriers are quality consistency, agricultural variability, oxidation, microbial control, and supplier qualification.

Natural raspberry inputs can be affected by:

• Crop yield and weather
• Geographic sourcing
• Seasonal availability
• Fruit maturity
• Pesticide exposure
• Color and flavor variability
• Transportation and cold-chain requirements
• Microbial contamination
• Concentration changes during processing

Synthetic flavor systems reduce agricultural exposure but introduce dependence on specialized aroma-chemical suppliers. A drug manufacturer may qualify separate natural and synthetic systems, but switching between them can require comparability work, stability testing, labeling review, and regulatory notification.

Anthocyanin-based red coloring has additional stability issues. Color intensity can change with pH, temperature, oxygen, light, metals, and processing conditions. For this reason, a raspberry-flavored product may use a separate colorant rather than relying on raspberry-derived pigments.

What is the commercial market outlook for raspberry pharmaceutical excipients?

Demand is concentrated in patient-centric oral dosage forms.

Market driver	Effect on raspberry demand
Pediatric drug development	Positive; increases need for palatable liquids and chewables
Orally disintegrating products	Positive; flavor is critical because dissolution occurs in the mouth
OTC consumer products	Positive; supports recognizable fruit profiles
Growth in generic pediatric products	Positive but price-sensitive
Clean-label positioning	Positive for natural raspberry materials
Cost pressure in generics	Favors synthetic or reconstructed flavor systems
Stability requirements	Limits use of natural fruit powders and anthocyanins
Injectable and hospital products	Minimal direct impact because flavor is usually irrelevant
Regulatory scrutiny of inactive ingredients	Raises qualification costs
Private-label competition	Increases price pressure and formulation outsourcing

The highest-value opportunities are not bulk raspberry flavor sales. They are integrated formulation services that combine flavor selection, taste masking, stability optimization, regulatory documentation, and scale-up support.

Flavor suppliers can capture greater value when they provide proprietary flavor systems, encapsulated flavors, bitterness-masking technologies, or platform formulations that reduce development time.

What is the financial trajectory for raspberry excipient suppliers?

Raspberry-specific revenue is generally not reported by public ingredient companies. Financial performance is usually embedded in broader segments such as flavors, fragrances, food ingredients, nutrition, or pharmaceutical excipients.

The category has a mixed financial profile:

• Volume growth is likely to be moderate rather than explosive.
• Pricing is higher for pharmaceutical-grade, documented, low-bioburden materials.
• Natural products can support premium pricing but face raw-material volatility.
• Synthetic blends generally have more predictable gross margins.
• Custom formulation work can produce better margins than commodity flavor sales.
• Qualification and regulatory support create switching costs.
• Supply disruptions can produce short-term price increases but may accelerate substitution.

A practical financial model should separate four revenue pools:

1. Commodity flavor ingredients.
2. Pharmaceutical-grade flavor systems.
3. Natural fruit-derived powders and concentrates.
4. Formulation development, taste-masking, and regulatory services.

The fourth pool has the strongest margin potential because it is linked to customer development programs and is less substitutable than a standard flavor concentrate.

What could improve margins?

Margin expansion is most likely from:

• Encapsulated or protected flavor systems
• Pediatric taste-masking platforms
• Ready-to-use premixes
• Low-sugar and sugar-free systems
• Stability-enhanced natural colors
• Direct supply agreements with drug manufacturers
• Regional manufacturing and dual-source qualification
• Regulatory packages tailored to pharmaceutical applications

Margin compression is likely where the product is sold as an interchangeable flavor concentrate and where customers can qualify several suppliers.

Which companies compete in pharmaceutical raspberry flavor supply?

Competition spans multinational flavor houses, pharmaceutical excipient suppliers, specialty ingredient manufacturers, and regional flavor formulators.

Relevant competitor groups include:

• Global flavor and fragrance companies
• Pharmaceutical excipient distributors
• Natural fruit ingredient producers
• Contract formulation and taste-masking specialists
• Regional suppliers serving generic-drug manufacturers

The competitive basis is not the raspberry name alone. Buyers evaluate:

• Flavor performance against the active ingredient
• Stability over shelf life
• Batch consistency
• Documentation quality
• Regulatory support
• Minimum order quantities
• Lead times
• Geographic redundancy
• Ability to customize the flavor profile
• Compatibility with sugar-free and alcohol-free formulations

Supplier concentration is higher for specialized pharmaceutical-grade systems than for ordinary food-grade raspberry flavors.

How does raspberry compare with other pharmaceutical flavors?

Flavor	Typical pharmaceutical positioning	Main advantage	Main limitation
Raspberry	Pediatric, sweet-tart, recognizable	Broad consumer acceptance	Can require color and acidity control
Strawberry	Pediatric and mass-market	Familiar and versatile	Can be difficult to distinguish at low concentration
Cherry	Syrups and cough products	Strong masking character	May have polarizing aftertaste
Grape	Pediatric liquids and chewables	Effective sweetness association	Can conflict with some active ingredients
Orange	Liquids and effervescent products	Strong citrus masking	Acidity and oxidation concerns
Mint	Oral care and adult products	Cooling and odor masking	Poor fit for many pediatric formulations
Vanilla	Suspensions, nutrition, and combination systems	Compatible with creamy profiles	Limited ability to mask very bitter drugs

Raspberry is commercially attractive when a manufacturer needs a fruit profile that is familiar but less medicinally associated than cherry or grape. It is less suitable where the active ingredient has strong sulfurous, metallic, or intensely bitter notes that require encapsulation or a more aggressive masking system.

What generic launch risks exist for raspberry-containing products?

Generic entry risk is generally high for simple raspberry-flavored oral products and lower for complex taste-masked systems.

High-risk products for originators

• Conventional syrups
• Basic oral solutions
• Standard chewable tablets
• Products using readily available flavor blends
• Formulations with no meaningful delivery technology
• Products protected only by broad, aging formulation claims

Lower-risk products for originators

• Multiparticulate systems
• Coated active particles
• Controlled-release products
• Complex suspensions
• Products with narrow stability windows
• Formulations requiring specialized manufacturing equipment
• Products supported by enforceable taste-masking or process patents

Generic manufacturers can usually select a different raspberry supplier or use a non-raspberry flavor without affecting bioequivalence, provided the inactive ingredients do not alter performance or safety.

What is the geographic coverage of raspberry excipient demand?

North America and Europe have mature pharmaceutical quality and regulatory requirements. Demand is supported by pediatric medicines, OTC products, and branded formulation development.

Asia-Pacific has the strongest long-term volume potential because of expanding generic manufacturing, pediatric healthcare access, contract development, and oral dosage-form production. India and China are important manufacturing bases, while Japan and South Korea maintain high quality and formulation standards.

Regional risks include:

• Different excipient documentation requirements
• Local food and drug standards
• Import controls
• Agricultural sourcing restrictions
• Currency volatility
• Variable enforcement of pharmaceutical-quality standards

A supplier with manufacturing or technical support in multiple regions has an advantage when customers require dual sourcing.

What licensing deals and litigation affect raspberry excipients?

There is no widely recognized licensing market for raspberry as a standalone pharmaceutical excipient. Licensing value generally arises from:

• Proprietary taste-masking technology
• Encapsulation or coating systems
• Branded flavor libraries
• Drug-specific formulation platforms
• Natural color stabilization systems
• Contract development agreements

Raspberry-related litigation is more likely to involve trademark, trade dress, supplier contracts, formulation patents, or finished-drug patents than ownership of the flavor itself. Patent litigation risk is highest where a raspberry formulation is part of a commercial pediatric, specialty, or controlled-release product with meaningful revenue.

Key Takeaways

• Raspberry is a flavor and formulation component, not a single standardized pharmaceutical excipient.
• Its main uses are taste masking, palatability improvement, and consumer-oriented flavoring in oral dosage forms.
• No standalone Orange Book exclusivity or broad patent monopoly protects raspberry.
• Patent value lies in the finished formulation, delivery system, manufacturing process, or taste-masking technology.
• Demand is strongest in pediatric medicines, chewables, oral liquids, gummies, and orally disintegrating products.
• Public companies generally do not disclose raspberry-specific revenue.
• Pharmaceutical-grade documentation, stability, and supply reliability support premium pricing.
• Natural raspberry materials carry greater variability and agricultural risk than synthetic or reconstructed flavor systems.
• Generic entry risk is high for simple flavored products and lower for technically complex taste-masked formulations.
• The strongest financial opportunity is in customized pharmaceutical flavor systems and formulation services rather than commodity raspberry ingredients.

Frequently Asked Questions

Is raspberry flavor safe in pediatric medicines?

It can be used when the specific flavoring substances and concentration are suitable for the intended product, route, and patient population. The finished drug application must support the identity, quality, and safety of the actual flavor system.

Can raspberry flavor be used in an FDA-approved generic drug?

Yes. A generic drug may use raspberry flavor if the inactive-ingredient composition is permissible and the product meets applicable pharmaceutical, bioequivalence, quality, and labeling requirements.

Does natural raspberry flavor have stronger patent protection than synthetic raspberry flavor?

No. Natural origin does not create patent protection. Any enforceable rights would depend on a specific composition, extraction process, stabilization technology, or formulation claim.

Are raspberry anthocyanins suitable for all oral liquid formulations?

No. Anthocyanin color stability can be affected by pH, oxygen, light, heat, and metal ions. Formulators often use separate color systems or stabilization strategies.

Can a drug manufacturer switch raspberry flavor suppliers without regulatory work?

Not automatically. A supplier change can affect composition, impurities, flavor profile, stability, manufacturing controls, and labeling. The required regulatory action depends on the product, jurisdiction, and material change.

References

1. European Medicines Agency. (2017). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations, Title 21: Food and drugs. https://www.ecfr.gov/current/title-21

4. U.S. Food and Drug Administration. (2016). Nonclinical studies for the safety evaluation of pharmaceutical excipients. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

6. Flavor and Extract Manufacturers Association. (n.d.). FEMA GRAS flavoring substances. https://www.femaflavor.org/gras-gras-informationools/gras-flavoring-substances

7. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.